Photo of Lowell E. Schnipper,  MD

Lowell E. Schnipper, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-2176
Fax: (617) 667-3915

Lowell E. Schnipper, MD

Beth Israel Deaconess Medical Center


  • Theodore W. and Evelyn G. Berenson Professor, Medicine, Harvard Medical School
  • Chief, Hematology/Oncology, Beth Israel Deaconess Medical Center
  • Clinical Director, Beth Israel Deaconess Medical Center Cancer Center, Beth Israel Deaconess Medical Center



  • Institutional Representative for BIDMC, Membership Committee
  • Member, Clinical Science Coordinating Committee
  • Member, Center Scientific Council
  • Chair, Membership Committee
  • Associate Director, Membership, Executive Committee
  • Deputy Associate Director, Clinical Science, Executive Committee

Research Abstract

Our long term interest is in 2 general areas:

1. Genomic instability: we have developed a model system with which to identify the emergence of DNA rearrangements that follow exposure to a specific stimulus, e.g., exposure to a viral oncoprotein such as the AdE1A, or polyoma middle T antigens. We have established that these oncoproteins are necessary but not sufficient for induction of DNA rearrangements. Recent work has focused on other factors that mediate the induction of genetic rearrangements. Differential display analyses demonstrated the presence of several unique cDNAs the expression of which is upregulated, which are homologues of known helicases and appear to have an important role in generating a rearrangement event.

2. Another interest is the basis of resistance and sensitivity to inhibitors of topoisomerase II. We have cloned the hamster cDNA for top II and demonstrated the point mutation associated with drug resistance, and have cloned the promoter of the human topII alpha gene. Using conditional mutants we have demonstrated that sensitivity and resistance to inhibitors of top II are correlated with expression of this enzyme, and that the latter is inversely correlated with resistance to alkylating agents.

3. A distinct focus of our research has been a longstanding series of clinical investigations that are evaluating the efficacy of high dose chemotherapy and autologous stem cell reinfusion as a novel therapy for patients with advance solid tumors, e.g., breast cancer, testis cancer, small cell carcinoma of the lung, recurrent malignant lymphoma (HD and NHL). The studies undertaken have been a product of a collaboration by investigators at the BIDMC and the DFCI, and have been performed by the Solid Tumor Autologous Program (STAMP). The thrust of the clinical studies being performed by this group is twofold: enhancing the efficacy of high dose therapy by identifying new agents to be incorporated into this experimental therapeutic context, and the studies designed to understand minimal residual disease (MRD) and develop novel approaches to its treatment -- specifically employing vaccine and other inmmunologic strategies.


Powered by Harvard Catalyst
  • Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol 2015. PubMed
  • Schnipper LE, Meropol NJ. Payment for cancer care: time for a new prescription. J Clin Oncol 2014; 32:4027-8. PubMed
  • Schnipper LE. Quality oncology practice initiative: an approach to solving the value equation. J Oncol Pract 2014; 10:219-20. PubMed
  • Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE. American society of clinical oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 2014; 32:1277-80. PubMed
  • Shih YC, Ganz PA, Aberle D, Abernethy A, Bekelman J, Brawley O, Goodwin JS, Hu JC, Schrag D, Temel JS, Schnipper L. Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol 2013; 31:4151-7. PubMed
  • Schnipper LE. The rising cost of cancer care: physicians take charge. J Oncol Pract 2012; 8:e87-8. PubMed
  • Peppercorn JM, Smith TJ, Helft PR, Debono DJ, Berry SR, Wollins DS, Hayes DM, Von Roenn JH, Schnipper LE, . American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 2011; 29:755-60. PubMed
  • Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM, Blum D, Ubel PA, Schnipper LE, . American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009; 27:3868-74. PubMed
  • Schnipper LE. Update in oncology. Ann Intern Med 2007; 147:775-82. PubMed
  • Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 2007; 25:4506-7; author reply 4508. PubMed
  • Pentz RD, Joffe S, Emanuel EJ, Schnipper LE, Haskell CM, Tannock IF. ASCO core values. J Clin Oncol 2006; 24:5780-2. PubMed